Inscripta, Inc. is a leading life science technology company helping to create the bioeconomy. It develops innovative, sustainable, and affordable biomanufacturing solutions for a variety of applications and industries, including agriculture, chemicals, animal and human health solutions, personal care, and pharmaceuticals. Inscripta uses GenoScaler, a proprietary next-generation microbial strain engineering platform based on over 200 patents and relying on ultra-high-throughput CRISPR technologies, and cutting-edge artificial intelligence and machine learning tools to manufacture and supply ingredients at scale under rapid timelines.

Recently, officials announced that the company has successfully completed scale-up runs and is moving into commercial manufacturing of an anti-aging skincare ingredient. Inscripta is engaged with commercial partners to deliver an ingredient product with demonstrated efficacy, superior quality, and consistency that will benefit branded manufacturers and their customers. Commercial biomanufacturing addresses serious challenges in sourcing plant-based ingredients. These challenges include the environmental footprint associated with current extractive sourcing and the limited depth and consistency of supply chains, which can negatively impact availability and affordability. In addition, biomanufacturing eliminates sensitizing impurities native to plant-based extracts.

“There is an incredible opportunity for the bioeconomy to meet global consumer demands, not just in personal care, but well beyond by improving sustainability, stabilizing supply chains, and reducing time to market,” according to Sri Kosaraju, Inscripta President and CEO. “We not only develop robust and productive strains, but we also create scalable manufacturing supply chains that deliver sought-after materials to market.”

Inscripta’s development program leveraged its GenoScaler technology, a novel and proprietary ultra-high-throughput, CRISPR-enabled platform designed to rapidly optimize microbial strains for biomanufacturing. This two-year effort yielded engineered strains with commercially relevant productivities and consistent performance across four orders of magnitude in bioreactor scale. This important milestone for Inscripta demonstrates that the GenoScaler technology enables rapid development of high-producing and scale-up ready strains.

In 2019, Inscripta developed the world’s first fully automated benchtop instrument for genome-scale engineering. The CRISPR-mediated, massively parallel platform enables researchers to engineer, in their own labs, microbial libraries containing the full breadth and scope of possible edit types. Among other things, the platform supports bio-industrial materials development and manufacturing.

Inscripta partners with large global companies looking to address customer needs for sustainable products as well corporate objectives for growth and scalable supply chains, say officials. Inscripta’s biotechnology platform provides its partners with access to innovation and complements their existing biotech capabilities. The company was founded in 2015. Inscripta moved its headquarters to Hacienda in early 2020.

For more information about Inscripta, Inc., please visit www.inscripta.com or www.linkedin.com/company/inscriptainc.